Project Grant R21AI186005
Award Date
8/9/24
Completion Date
7/31/26
Dollars Obligated
$261K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Similar Awards
This federal Project Grant award of $466,500.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop rapid and ultrasensitive aptamer-based detection technologies for the diagnosis of Treponema pallidum infections, the causative agent of syphilis. The key products and services to be delivered through this funding include: 1) Developing aptamers that strongly and specifically bind to T....
The University of Texas at Austin received a $212,357 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The goal of this project is to develop a rapid, sensitive, and specific point-of-care diagnostic test for detecting congenital syphilis in newborns, as well as an improved maternal syphilis diagnostic using vaginal self-swabs. The key products to be delivered include: A...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $163,698 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Magic Lifescience, Inc. in Mountain View, CA to develop a novel point-of-care molecular diagnostic assay for syphilis as part of a multiplexed genital ulcer disease (GUD) test panel. The key objectives are to: 1) develop a PCR-based, multiplexed molecular assay for Treponema pallidum (syphilis) and other GUD pathogens using giant...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $233,250 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Washington to develop and validate a rapid, point-of-care molecular test to detect Treponema pallidum antibiotic resistance. The key products to be delivered under this 2-year grant include: A multiplexed, point-of-care allele-specific loop-mediated isothermal amplification (AS-LAMP) assay to detect genetic markers of...
This federal Project Grant award, valued at $771,690.00 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate syphilis pathogenesis through genetic engineering of the syphilis-causing bacteria Treponema pallidum. The award aims to leverage new capabilities to genetically manipulate T. pallidum in order to better understand the role of antigenic variation in the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $499,151 to Virginia Polytechnic Institute & State University (Virginia Tech) to develop a novel diagnostic platform for detecting syphilis infection. The key objective is to create an immuno-PCR diagnostic tool that can specifically detect released peptidoglycan fragments from the bacterium that causes syphilis, Treponema pallidum....
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop an integrated multiplexed diagnostic assay for the rapid detection and semi-quantification of treponemal and nontreponemal antibodies associated with syphilis. The $698,349 award will fund the creation of an electrochemical sensing platform that can simultaneously identify active syphilis infections and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to optimize molecular polymerase chain reaction (PCR) testing for the detection of congenital syphilis. The $246,000 award, effective August 20, 2024 through July 31, 2026, will fund research to determine the optimal diagnostic specimen(s) and sampling strategy for PCR-based detection of Treponema pallidum in...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund the development of a novel suite of local-level syphilis epidemiologic and economic models (LSEEM) across 40 U.S. cities with the highest syphilis diagnosis rates. The $1,550,917 award, spanning from July 2024 to May 2029, aims to assess the potential impact of scaling up existing syphilis control...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $205,000 to the Regents of the University of California, San Francisco (UCSF) to conduct research aimed at identifying novel biomarkers for the diagnosis of syphilis in pregnancy and assessment of treatment response. The key objectives of this 2-year project include: 1) analyzing longitudinal samples from...